Medisana AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Sadif Analytics Prime
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Medisana AG Adjusts FY 2013 Outlook
Medisana AG announced that following the end of the third quarter and the preparation of preliminary figures, the Management Board is no longer assuming that the Company will return to operating profitability in its current financial year, despite a slight increase in sales revenue and improved results. This is attributable to delays of sales revenues to subsequent quarters and lower demand in important product groups due to unfavorable weather conditions. Although the current fourth quarter is traditionally the Company's strongest quarter in terms of sales revenue and earnings, the Management Board anticipates that the operating result for the full 2013 financial year will continue to comprise a loss, although reflecting an improvement on the previous year's operating result.
Latest Key Developments in Pharmaceuticals
- Sanjivani Paranteral Ltd announces change in management and appoints auditors
- Concordia Healthcare Corp. provides clinical trial and corporate update
- NEL ASA proceeds of 65 million Norwegian crowns in private placement
- Sawai Pharmaceutical Co Ltd updates on business acquisition from subsidiary of Mitsubishi Tanabe Pharma
- Share this
- Digg this